-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
ARS Pharmaceuticals, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2020 to Q3 2024.
- ARS Pharmaceuticals, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$21.7M, a 21% decline year-over-year.
- ARS Pharmaceuticals, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$60.5M, a 16.8% increase year-over-year.
- ARS Pharmaceuticals, Inc. annual Operating Income (Loss) for 2023 was -$67.5M, a 90.1% decline from 2022.
- ARS Pharmaceuticals, Inc. annual Operating Income (Loss) for 2022 was -$35.5M, a 82.6% decline from 2021.
- ARS Pharmaceuticals, Inc. annual Operating Income (Loss) for 2021 was -$19.5M, a 40.9% increase from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)